Abstracts tagged "fractures"

Abstract Number: 326 • 2017 ACR/ARHP Annual Meeting
Osteoporosis and Vertebral Fractures Are Associated with Disease Activity, Low Vitamin D Levels and Spinal Radiographic Damage in Patients with Axial Spondyloarthritis
Cintia Romera-López¹, Cristina Fernández-Carballido², Miguel Ángel García-Moreno³ and Teresa Pedraz⁴, ¹Rheumatology, Hospital Universitario del Vinalopó, Elche, Spain, ²Hospital General Universitario de Elda, Elda, Spain, ³Hosppital Universitario de Elda, Elda, Spain, ⁴Hospital Universitario de Elda, Elda, Spain
Background/Purpose: Osteoporosis and vertebral fractures are comorbidities of Axial Spondyloarthritis (axSpA). We evaluated the relationship between disease activity and radiographic damage and bone mineral density…
Abstract Number: 328 • 2017 ACR/ARHP Annual Meeting
Secular Trends in the Risk of Fragility Fracture Among Patients with Rheumatoid Arthritis: A General Population-Based Study
Sarah Keller¹, Marcy B. Bolster², Amar Oza³, Sharan K. Rai⁴, Leo Lu³, Yuqing Zhang⁵ and Hyon K. Choi⁴, ¹Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁵Department of Rheumatology, Allergy and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: The risk of osteoporotic (OP) fracture among patients with rheumatoid arthritis (RA) is higher than that of the general population. The worldwide incidence of…
Abstract Number: 1094 • 2017 ACR/ARHP Annual Meeting
A Model for Improved Management of Fragility Fractures: Navigating the Fracture Liaison Service
Marcy B. Bolster¹, Smriti Cevallos², Lisa Beyer², Henry M. Kronenberg² and Ben Leder², ¹Massachusetts General Hospital, Boston, MA, ²Endocrine, Massachusetts General Hospital, Boston, MA
Background/Purpose: Fragility fractures are associated with significant morbidity, mortality and healthcare costs, yet most fracture patients are neither evaluated nor treated for their underlying osteoporosis…
Abstract Number: 1214 • 2017 ACR/ARHP Annual Meeting
Fracture Incidence and Characteristics in Young Adults Age 18 to 49 Years: A Population-Based Study
Joshua N. Farr¹, L. Joseph Melton III¹, Sara J. Achenbach¹, Elizabeth J. Atkinson¹, Sundeep Khosla¹ and Shreyasee Amin², ¹Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: While fractures in both the elderly and pediatric populations have been extensively investigated, comparatively little attention has been given to the age-group in between.…
Abstract Number: 1217 • 2017 ACR/ARHP Annual Meeting
Evaluation of Post Fracture Management in Males at a Veterans Affairs Health System
Nicola Berman¹, David Smith², Virginia Pike³, Craig Tenner⁴, Michael Pillinger¹ and Stephen Honig¹, ¹Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ²School of Medicine, New York University School of Medicine, New York, NY, ³Medicine/Rheumatology, New York University School of Medicine, Division of Rheumatology, New York, NY, ⁴New York University School of Medicine, Internal Medicine, New York, NY
Background/Purpose: The worldwide incidence of hip fractures in men is rising, and by 2050 is projected to increase by 310%. Increased hip fracture rates may…
Abstract Number: 1890 • 2017 ACR/ARHP Annual Meeting
Persistent Fracture Reduction with Abaloparatide-SC (TYMLOS™) Followed By 24 Months of Alendronate
Kenneth Saag¹, Paul D Miller², Felicia Cosman^3,4, Lorraine A Fitzpatrick⁵, Gary Hattersley⁶, Robert Gut⁶, Bruce Mitlak⁶, John P Bilezikian⁴ and Robin K Dore⁷, ¹Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ²Colorado Center for Bone Research, Lakewood, CO, ³Helen Hayes Hospital, West Haverstraw, NY, ⁴Columbia University College of Physicians and Surgeons, New York, NY, ⁵Chief Medical Officer, Radius Health, Inc., Waltham, MA, ⁶Radius Health, Inc., Waltham, MA, ⁷Robin K Dore, MD, Inc., Tustin, CA
Background/Purpose: In the ACTIVE phase III trial, postmenopausal women with osteoporosis were randomized 1:1:1 to abaloparatide (ABL; n=824), blinded placebo (PBO; n=821), or open-label teriparatide…
Abstract Number: 2920 • 2017 ACR/ARHP Annual Meeting
Comparative Rates of Osteoporotic Fractures Among U.S. Medicaid Enrollees with and without Systemic Lupus Erythematosus
Sara K. Tedeschi¹, Beatrice Pan¹, Hongshu Guan¹, Seoyoung C. Kim², Daniel H. Solomon¹ and Karen H. Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, ²Division of Pharmacoepidemiology and Pharmocoeconomics, Brigham and Women's Hospital, Boston, MA
Background/Purpose: Fractures are potentially avoidable and highly morbid. We studied non-vertebral fracture rates among SLE patients enrolled in Medicaid, the U.S. health insurance program for…
Abstract Number: 1796 • 2016 ACR/ARHP Annual Meeting
Osteoporosis and Vertebral Fractures in Patients with Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Mario García-Carrasco^1,2, Pamela Soto-Santillan³, Samanda Adriana Rojas villarraga⁴, Nicolás Molano-González⁵ and Claudia Mendoza Pinto⁶, ¹Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico, ²Inmunología y Reumatología, Universidad Autónoma de Puebla, Puebla, Mexico, ³Internal Medicine, Systemic Autoimmune Diseases Research Unit, IMSS, Puebla, México, Puebla, Mexico, ⁴Novartis de Colombia, Bogota, Colombia, ⁵Center for Autoimmune Diseases Research (CREA). School of Medicine and Health Sciences, Universidad del Rosario, Bogotá, Colombia., Bogota, Colombia, ⁶Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR, IMSS, Puebla, Mexico
Background/Purpose: Observational studies have indicated a high but heterogeneous prevalence of low bone mineral density (BMD) and vertebral fractures (FV) in patients with systemic lupus…
Abstract Number: 21 • 2016 ACR/ARHP Annual Meeting
Outcomes of Rheumatoid Arthritis Patients with Hip Fracture
Lucy Liu¹, Joan Lo² and Malini Chandra³, ¹Internal Medicine, Kaiser Permanente, Oakland, CA, ²Endocrinology, Kaiser Permanente, Oakland, CA, ³Kaiser Permanente, Oakland, CA
Background/Purpose: Rheumatoid arthritis (RA) is a well-known risk factor for osteoporosis and hip fracture. Recent studies suggest RA patients fracture at a younger age and…
Abstract Number: 334 • 2016 ACR/ARHP Annual Meeting
Predictors of Fragility Fractures in Patients with Rheumatoid Arthritis Not on Steroids: An Observational Study
Sarah Dyball¹ and Marwan Bukhari², ¹University Hospital South Manchester, Manchester, United Kingdom, ²Royal Lancaster Infirmary, Lancaster, United Kingdom
Background/Purpose: Patients with rheumatoid arthritis (RA) have an increased fracture risk, however, this is confounded by a coexisting use of steroids. This study aims…
Abstract Number: 336 • 2016 ACR/ARHP Annual Meeting
The Risk of Subsequent Osteoporotic Fractures Is Decreased in Patients Experiencing Fracture While on Denosumab
DL Kendler¹, A Chines², ML Brandi³, S Papapoulos⁴, EM Lewiecki⁵, J-Y Reginster⁶, C Roux⁷, M Munoz Torres⁸, A Wang² and HG Bone⁹, ¹University of British Columbia, Vancouver, BC, Canada, ²Amgen Inc., Thousand Oaks, CA, ³University of Florence, Florence, Italy, ⁴Leiden University Medical Center, Leiden, Netherlands, ⁵New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁶University of Liège, Liège, Belgium, ⁷Paris Descartes University, Paris, France, ⁸Hospital Universitario San Cecilio, Granada, Spain, ⁹Michigan Bone and Mineral Clinic, Detroit, MI
Background/Purpose: Osteoporosis is a common, progressive condition leading to increased bone fragility and susceptibility to fracture. Although osteoporosis therapy decreases fracture risk, fractures while on…
Abstract Number: 337 • 2016 ACR/ARHP Annual Meeting
Denosumab Treatment for 10 Years in Postmenopausal Women with Osteoporosis Was Associated with Substantially Lower Fracture Incidence Relative to Their Baseline FRAX-Predicted Probability
E Siris¹, N Pannacciulli², PD Miller³, EM Lewiecki⁴, R Chapurlat⁵, E Jódar-Gimeno⁶, NS Daizadeh², RB Wagman² and JA Kanis⁷, ¹Columbia University Medical Center, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³Colorado Center for Bone Research, Lakewood, CO, ⁴New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ⁵Hôpital Edouard Herriot, Lyon, France, ⁶Hospital Universitario Quirónsalud Madrid, Madrid, Spain, ⁷University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Denosumab is approved for treating postmenopausal women with osteoporosis at high risk for fracture. The placebo-controlled FREEDOM trial and its active-treatment Extension investigated the…
Abstract Number: 345 • 2016 ACR/ARHP Annual Meeting
The Relationship Between Anti-Cyclic Citrullinated Peptide (anti-CCP) Levels and Bone Mineral Density (BMD) or Fragility Fracture in Patients with Rheumatoid Arthritis (RA)
Tien-Tsai Cheng^1,2, Yin-Chou Chen^1,2, Shan-Fu Yu^1,2, Han-Ming Lai^1,2, Ben Yu-Jih Su^1,2, Fu-Mei Su^2,3, Wen-Chan Chiu^1,2, Chung-Yuan Hsu^1,4, Jia-Feng Chen¹ and Chi-Hua Ko¹, ¹Division of Allergy, Immunology and Rheumatology, Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, ²Chang Gung University College of Medicine, Kaohsiung, Taiwan, ³Chang Gung Memorial Hospital at Kaohsiung, Kaohsiung, Taiwan, ⁴Division of Rheumatology, Allergy, and Immunology, Chang Gung University College of Medicine, Kaohsiung, Taiwan
Background/Purpose: To explore the relationship of anti-CCP levels with BMD or fragility fracture in patients with RA Methods: This is a prospective cross sectional study.…
Abstract Number: 895 • 2016 ACR/ARHP Annual Meeting
Incidence of Osteoporotic Mayor Fractures in a Cohort of Patients with Polymyalgia Rheumatica
Luciano Enrique Pompermayer¹, Ignacio Javier Gandino¹, Maximiliano José Martinez¹, Florencia Beatriz Mollerach¹, Marina Scolnik², Javier Rosa¹ and Enrique R. Soriano¹, ¹Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires, and Fundacion PM Catoggio, Argentina., Buenos Aires, Argentina
Background/Purpose: Polymyalgia rheumatica (PMR) is an inflammatory disease associated with older age and long term use of glucocorticoids. As such a high incidence of osteoporosis…
Abstract Number: 1023 • 2016 ACR/ARHP Annual Meeting
Fracture Risk Reduction with Romosozumab: Results of a Phase 3 Study in Postmenopausal Women with Osteoporosis
F Cosman¹, DB Crittenden², JD Adachi³, N Binkley⁴, E Czerwinski⁵, S Ferrari⁶, LC Hofbauer⁷, E Lau⁸, EM Lewiecki⁹, A Miyauchi¹⁰, CAF Zerbini¹¹, CE Milmont², L Chen², J Maddox², PD Meisner¹², C Libanati¹² and A Grauer², ¹Helen Hayes Hospital, West Haverstraw, and Columbia University, New York, NY, ²Amgen Inc., Thousand Oaks, CA, ³McMaster University, Hamilton, ON, Canada, ⁴University of Wisconsin–Madison Osteoporosis Clinical Center and Research Program, Madison, WI, ⁵Krakow Medical Center, Krakow, Poland, ⁶Geneva University Hospital, Geneva, Switzerland, ⁷Division of Endocrinology, Diabetes, and Bone Diseases, TU Dresden Medical Center, Dresden, Germany, ⁸Center for Clinical and Basic Research, Hong Kong, China, ⁹New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, ¹⁰Miyauchi Medical Center, Osaka, Japan, ¹¹Centro Paulista de Investigação Clinica, São Paulo, Brazil, ¹²UCB Pharma, Brussels, Belgium
Background/Purpose: Romosozumab (Romo) is an investigational bone-forming monoclonal antibody that binds sclerostin and has a dual effect, increasing bone formation and decreasing bone resorption. Here,…